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Abstract
Vaccines are proving to be highly effective in controlling hospitalisation and deaths associ-
ated with SARS-CoV-2 infection but the emergence of viral variants with novel antigenic pro-
files threatens to diminish their efficacy. Assessment of the ability of sera from vaccine
recipients to neutralise SARS-CoV-2 variants will inform the success of strategies for mini-
mising COVID19 cases and the design of effective antigenic formulations. Here, we exam-
ine the sensitivity of variants of concern (VOCs) representative of the B.1.617.1 and
B.1.617.2 (first associated with infections in India) and B.1.351 (first associated with infec-
tion in South Africa) lineages of SARS-CoV-2 to neutralisation by sera from individuals vac-
cinated with the BNT162b2 (Pfizer/BioNTech) and ChAdOx1 (Oxford/AstraZeneca)
vaccines. Across all vaccinated individuals, the spike glycoproteins from B.1.617.1 and
B.1.617.2 conferred reductions in neutralisation of 4.31 and 5.11-fold respectively. The
reduction seen with the B.1.617.2 lineage approached that conferred by the glycoprotein
from B.1.351 (South African) variant (6.29-fold reduction) that is known to be associated
with reduced vaccine efficacy. Neutralising antibody titres elicited by vaccination with two
doses of BNT162b2 were significantly higher than those elicited by vaccination with two
doses of ChAdOx1. Fold decreases in the magnitude of neutralisation titre following two
doses of BNT162b2, conferred reductions in titre of 7.77, 11.30 and 9.56-fold respectively to
B.1.617.1, B.1.617.2 and B.1.351 pseudoviruses, the reduction in neutralisation of the delta
variant B.1.617.2 surpassing that of B.1.351. Fold changes in those vaccinated with two
doses of ChAdOx1 were 0.69, 4.01 and 1.48 respectively. The accumulation of mutations in
these VOCs, and others, demonstrate the quantifiable risk of antigenic drift and subsequent
reduction in vaccine efficacy. Accordingly, booster vaccines based on updated variants are
likely to be required over time to prevent productive infection. This study also suggests that
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Author summary
The SARS-CoV-2 virus is likely to have emerged following a cross-species jump from bats
to humans in Wuhan, China at the end of 2019. As the virus has evolved to adapt to
humans, new viral variants have emerged that incorporate mutations in the “spike” gene.
The spike protein is expressed on the surface of the virus, it facilitates entry into human
cells and is the main target of neutralising antibodies. Mutations change the shape of the
spike protein, preventing antibody recognition and enabling the virus to escape from the
immunity induced by vaccination. Using samples collected from vaccinated people as part
of the COVID-19 Deployed Vaccine Cohort Study (DOVE), we assessed the capacity of
different variants (beta, kappa and delta) to evade the protective immune response in
recipients of the Astra Zeneca ChAdOx1 and Pfizer BNT162b2 vaccines, both of which
are based on the early Wuhan virus spike gene. We noted a reduction in neutralisation of
both the beta and delta variants by vaccine sera from recipients of both vaccines. While
vaccines remain highly effective at preventing severe infection and death, ongoing moni-
toring of vaccine effectiveness is indicated as the virus continues to evolve over time, espe-
cially in vulnerable groups.
Introduction
The B.1.617.2 (Delta) variant that spread from India in March 2021 is now the dominant
SARS-CoV-2 variant type in the United Kingdom [1], replacing the B.1.1.7 (Alpha; “Kent”)
variant and spreading rapidly across the globe. The B.1.617.2 variant has been introduced into
the UK on multiple occasions, most commonly associated with international travel from India
where it has caused a large wave of COVID-19 infections and placed unprecedented demand
on healthcare services [2]. A key component of the UK response to COVID-19 is a campaign
of mass vaccination, prioritizing the population by age and other risk groups. Vaccination
began in December 2020 using the BNT162b2 mRNA vaccine (PfizerBioNTech). The ChA-
dOx1 adenovirus vectored vaccine (Oxford-AstraZeneca) was added from January 2021, with
the mRNA-1273 vaccine (Moderna) available from April 2021. Priority was given to adminis-
tering the first dose of vaccine to as much of the UK population as possible, with second doses
given within 12 weeks, in line with the guidance of the Joint Committee on Vaccination and
Immunisation (JCVI). This delayed dosing strategy is now being challenged by the emergence
of the B.1.617.2 lineage of SARS-CoV-2. Recent data from Public Health England suggest that
following exposure to this lineage, effectiveness of the BNT162b2 vaccine is reduced to 33.5%
after one dose, and 87.9% following two doses [3]. Further, the two-dose effectiveness of the
ChAdOX1 vaccine is reduced to 59.8% following exposure to B.1.617.2 [3].
The early virus sequences detected in India were reported to have two key amino acid sub-
stitutions (L452R and E484Q) in the receptor-binding domain of the spike glycoprotein, the
main immunodominant region and the region involved in ACE2 binding. Accordingly, this
resulted in the widespread usage of the “double mutant” misnomer, and initial designation as
the B.1.617 Pango lineage. Availability of further sequence data led to the assignment of sub-
lineages: B.1.617.1, B.1.617.2 and B.1.617.3, of which B.1.617.2 is now the dominant variant in
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the UK. The three lineages are characterized by the spike mutation L452R, whilst E484Q is
present in B.1.617.1 and B.1.617.3 but not B.1.617.2. The substitution L452R has been shown
previously to reduce binding by several monoclonal antibodies [4,5,6,7,8] and convalescent
plasma [6]. Globally, L452R has emerged independently in several lineages since November/
December 2020 suggesting a role in immune-evasion and/or virus adaptation [9]. L452R is
one of the defining mutations of the lineage B.1.427/B.1.429, a variant of interest (VOI) first
identified in California and associated with reduced neutralisation titres with plasma from vac-
cinated or convalescent individuals [7]. Investigation of the effect of RBD mutations on bind-
ing of convalescent plasma by deep mutational scanning suggests the impact of E484Q is
similar to that of E484K [10], which has been shown widely to diminish antibody binding,
including those elicited by vaccination [8,11].
In this study, we investigated the neutralising capacity of sera from participants in the
COVID-19 DeplOyed VaccinE (DOVE) Cohort Study who had been vaccinated with the
BNT162b2 mRNA vaccine (Pfizer-BioNTech) or the ChAdOx1 adenovirus-vectored vaccine
(Oxford-AstraZeneca) as part of the national deployed vaccine strategy.
Materials and methods
Ethics statement
All participants gave written informed consent to take part in the study. The study was
approved by the North-West Liverpool Central Research Ethics Committee (REC reference
21/NW/0073).
Serum samples
Serum samples were collected from healthy volunteers participating in the COVID-19
Deployed Vaccine Cohort Study (DOVE), a cross-sectional cohort study to determine the
immunogenicity of deployed COVID-19 vaccines against evolving SARS-CoV-2 variants.
DOVE is a post-licensing cross-sectional cohort study of individuals vaccinated with deployed
vaccines as part of the UK response to the COVID-19 pandemic. Adult volunteers aged at least
18 years, were recruited into the observational study at 14 days post first or second dose of
vaccine.
Preparation of SARS-CoV-2 antigens for ELISA
S1 and RBD antigens were prepared as described previously [12]. Briefly, the SARS-CoV-2
RBD and S1 constructs, spanning SARS-CoV-2 S (UniProt ID P59594) residues 319–541
(RVQPT. . .KCVNF) and 1–530 (MFVFL. . .GPKKS), respectively, were produced with C-ter-
minal twin Strep tags in the mammalian expression vector pQ-3C-2xStrep38. A signal peptide
from immunoglobulin kappa gene product (METDTLLLWVLLLWVPGSTGD) was used to
direct secretion of the RBD construct. Proteins were produced by transient expression in
Expi293F cells growing in FreeStyle 293 medium. Conditioned media containing secreted pro-
teins were harvested at two timepoints, 3–4 and 6–8 days post-transfection. Twin Strep-tagged
proteins were captured on Streptactin XT (IBA LifeSciences), eluted, and then purified to
homogeneity by size exclusion chromatography through Superdex 200 (GE Healthcare). Puri-
fied SARS CoV2 antigens, concentrated to 1–5 mg/ml by ultrafiltration were aliquoted and
snap-frozen in liquid nitrogen prior to storage at -80˚C.
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ELISA for SARS-CoV-2 antibodies
ELISAs for SARS-CoV-2 antibodies were performed as described previously [13]. Briefly,
96-well plates were coated overnight at 4˚C with purified SARS-CoV-2 antigens in phosphate-
buffered saline (PBS). Wells were blocked for 1 hr at room temperature in blocking buffer con-
sisting of PBS with 0.05% Tween 20 (PBS/Tween) and 1X casein (Vector labs., Peterborough,
UK). Plates were then washed 3x in PBS/Tween prior to incubation with 50μL of each serum
sample diluted 1:100 in blocking buffer. Each plate included two pooled negative controls and
two pooled positive controls. Sera were incubated for 1 hour at room temperature. Plates were
then washed 3x with PBS/Tween, before incubation for 1 hour with horseradish peroxidase
(HRP)-conjugated rabbit anti-human IgG (Bethyl labs., Cambridge Bioscience, Cambridge,
UK) diluted 1:2500 in blocking buffer. Plates were washed a further 3x in PBS/Tween before
addition of the 3,30,5,50-tetramethylbenzidine (TMB) liquid substrate (Sigma Aldrich, Merck,
Dorset, UK). Colour development was allowed to proceed for 10 minutes before the addition
of 1M H2SO4 stop solution, at which point the absorbance was determined at 450nm on a
Multiskan FC plate reader. Full validation of the S1 and RBD ELISA has been described previ-
ously [13].
Measurement of neutralising antibody activity using viral pseudotypes
HEK293, HEK293T, and 293-ACE2 cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% foetal bovine serum, 200mM L-glutamine, 100μg/
ml streptomycin and 100 IU/ml penicillin. HEK293T cells were transfected with the appropri-
ate SARS-CoV-2 S gene expression vector (wild type or variant) in conjunction with p8.91
[14] and pCSFLW [15] using polyethylenimine (PEI, Polysciences, Warrington, USA). HIV
(SARS-CoV-2) pseudotypes containing supernatants were harvested 48 hours post-transfec-
tion, aliquoted and frozen at -80˚C prior to use. The SARS-CoV-2 spike glycoprotein expres-
sion construct for Wuhan-Hu-1 was obtained from Nigel Temperton, University of Kent. The
S gene of B.1.351 (South Africa) was based on the codon-optimised sequence of the Wuhan-
Hu-1 expression construct, synthesised by Genscript (Netherlands) and sub-cloned into the
pCDNA6 expression vector. S gene constructs bearing the B.1.617.1 and B.1.617.2 S genes
were based on the codon-optimised spike sequence of SARS-CoV-2 [16] and generated using
the QuikChange Multi Site-Directed Mutagenesis Kit (Agilent, USA). Constructs bore the fol-
lowing mutations relative to the Wuhan-Hu-1 sequence (GenBank: MN908947): B.1.351 –
D80A, D215G, L241-243del, K417N, E484K, N501Y, D614G, A701V; B.1.617.1 –T95I,
G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H; B.1.617.2 –T19R, G142D, E156del,
F157del, R158G, L452R, T478K, D614G, P681R, D950N. 293-ACE2 target cells [13] were
maintained in complete DMEM supplemented with 2μg/ml puromycin.
Neutralising activity in each sample was measured by a serial dilution approach. Each sam-
ple was serially diluted in triplicate from 1:50 to 1:36450 in complete DMEM prior to incuba-
tion with HIV (SARS-CoV-2) pseudotypes, incubated for 1 hour, and plated onto 239-ACE2
target cells. After 48–72 hours, luciferase activity was quantified by the addition of Steadylite
Plus chemiluminescence substrate and analysis on a Perkin Elmer EnSight multimode plate
reader (Perkin Elmer, Beaconsfield, UK). Antibody titre was then estimated by interpolating
the point at which infectivity had been reduced to 90% of the value for the no serum control
samples.
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Results
Characterisation of B.1.617.2 spike sequences
The B.1.617.2 lineage has spread rapidly across the globe following detection in India in late
2020. According to GISAID (https://www.gisaid.org - accessed on 10/06/2021), a total of
31,997 sequences (Europe = 24,606, Asia = 4,974, North America = 2,210, Oceania = 163,
Africa = 36, South America = 8) have been assigned to lineage B.1.617.2, predominantly from
the UK (n = 22,619; reflecting the large-scale UK sequencing effort). The first B.1.617.2
sequence in the UK occurred on the 18th March 2021 when the dominant UK lineage was
B.1.1.7, and since the end of May 2021, B.1.617.2 accounts for the majority of SARS-CoV-2
samples sequenced (Fig 1A). In order to make sure that our available reagents matched the
majority of the circulating B.1.617.2 variants, we assessed the relative frequency of each spike
mutation in all the available sequences (Fig 1B). Amino acid substitutions T19R, G142D,
R158G, L452R, T478K, D614G, P681R, D950N and deletion Δ156–157 were present in the
majority of the B.1.617.2 variants as chosen in the spike constructs used in our assays described
below. The B.1.617.2 lineage continues to evolve, acquiring new mutations of concern such as
K417N in the sub-lineage AY.1/B.1.617.2.1 (Fig 1B).
Although each Pango lineage has a distinct mutation set, there are several similarities
between the spike mutational profiles of the VOCs B.1.351, B.1.1.7 and B.1.617.2 (Fig 2). They
each have a deletion within the N-terminal domain supersite (NTDSS), at least one mutation
in the receptor binding motif (RBM), and B.1.1.7 and B.1.617.2 each have a mutation at P681
within the furin cleavage site.
Antibody response post-vaccination
Sera were collected from 156 healthy individuals who had received one dose (n = 37) or two
doses (n = 50) of BNT162b2 (Pfizer-BioNTech), or one dose (n = 50) or two doses (n = 18) of
ChAdOx1 (Oxford/AstraZeneca) vaccines. Samples were screened initially by ELISA for reac-
tivity with recombinant S1, RBD and N from the Wuhan-Hu-1 SARS-CoV-2 sequence. Of
those individuals vaccinated with BNT162b2, only one individual given a single dose (1/37)
failed to mount a detectable antibody response against S1, all other samples were positive for
reactivity against both S1 and RBD (Fig 3A). In contrast, four individuals given a single dose
(4/50) of ChAdOx1 failed to react with S1, although two of these samples bound the RBD anti-
gen (Fig 3B). All samples from individuals immunised with two doses of either BNT162b2 or
ChAdOx1 reacted strongly against both S1 and RBD. Antibody reactivity (A450nm) was sig-
nificantly higher following the second dose of either BNT162b2 (S1 and RBD, p<0.0001) or
ChAdOx1 (S1 p = 0.0006; RBD p = 0.0014) compared with a single dose of the respective vac-
cines. Moreover, reactivity against S1 was significantly greater in the groups immunised with
either one (p = 0.0152) or two (p = 0.0145) doses of BNT162b2 in comparison with the groups
immunised with one or two doses of ChAdOx1 respectively. Similarly, reactivity against RBD
was higher in samples from the groups immunised with either one (p = 0.0029) or two
(p = 0.0018) doses of BNT162b2 in comparison with one or two doses of ChAdOx1 respec-
tively. Eight individuals were identified with reactivity against SARS-CoV-2 N suggesting
prior, undocumented exposure to SARS-CoV-2 or a related coronavirus. Exclusion of samples
from these individuals did not affect the analyses (S1 Table).
Neutralising antibody response
Neutralising antibodies were measured against HIV(SARS-CoV-2) pseudotypes expressing
spike glycoproteins from either the vaccine sequence (Wuhan-Hu-1), or the variants B.1.617.1,
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Fig 1. Emergence of B.1.617.2 in the UK. (A). Weekly SARS-CoV-2 genome sequences of delta/B.1.617.2 (pink),
alpha/B.1.1.7 (grey), and all other lineages (blue) in the UK, represented as a (stacked) percentage of all UK sequences
that week, up to the week beginning 29th May 2021. Heatmap visualisation of spike mutations within UK B.1.617.2
SARS-CoV-2 genome sequences (B). Columns represent different amino acid mutations within the spike protein,
whilst rows represent different specific combinations of spike mutations (“backbones”). Only non-synonymous
mutations (blue or pink for those with a known antigenic effect) and deletions (black) were considered, and only
backbones observed 10 or more times are displayed. The observed frequency for each backbone is visualised in the
Freq column whilst the antigenic column represents the total number of known antigenic mutations in the backbone;
the backbone from the AY.1 lineage (derived from Nepal; containing mutations W258L and K417N) is also included
(top row). The heatmap is hierarchically clustered based on the Euclidean distance between spike backbones (rows);
backbones missing specific mutations/deletions could be indicative of Ns (failed amplicons) in the genome sequence at
those sites rather than true absence.
https://doi.org/10.1371/journal.ppat.1010022.g001
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B.1.617.2 and B.1.351. Antibody titres were estimated by interpolating the point at which
Fig 2. Spike mutations within variants of concern. (A) Non-synonymous mutations (pink) and deletions (black) are
shown for the variants of concern: B.1.1.7, B.1.351, B.1.617.1 and B.1.617.2, and P.1. Purple is used to distinguish secondary
non-synonymous mutations at the same position, for example E484K (pink) and E484Q (purple). The region of the spike
protein the mutation is located is highlighted on the top row; N-terminal domain (NTD), NTD antigenic supersite
(NTDSS), receptor binding domain (RBD), receptor binding motif (RBM), furin cleavage site, S1 (NTD, NTDSS, RBD,
RBM and furin are also in S1) and S2 subunits. Spike protein structure showing key B.1.617.2 mutations (B). Surface
representation of spike homotrimer in open conformation with one upright RBD overlaid with ribbon representation
(RCSB Protein Data Bank ID 6ZGG [26], with different monomers shown in black, pale blue and gold. Residues involved in
B.1.617.2 lineage defining substitutions or deletions are shown as red spheres on each of the three monomers and are
labelled on the monomer with an upright RBD, shown in black. Scissors mark the approximate location of an exposed loop
(residues 677–688), containing the furin cleavage site, and including residue 681, which is absent from the structure.
https://doi.org/10.1371/journal.ppat.1010022.g002
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Fig 3. Antibody response elicited by SARS-CoV-2 vaccines. Sera from participants in the DOVE study were analysed
by ELISA or pseudotype-based neutralisation assay. (A, B) ELISA reactivity in sera from individuals vaccinated with
one or two doses of either BNT162b2 (A) or ChAdOx1 (B) was measured against recombinant S1 and RBD. Each
point represents A450nm, cut-offs for S1 and RBD respectively are denoted by dotted lines. (C-F) Neutralising
antibodies from individuals vaccinated with one or two doses of BNT162b2 (C and D) or ChAdOx1 (E and F) were
quantified against HIV(SARS-CoV-2) pseudotypes bearing the Wuhan-Hu-1, B.1.617.1, B.1.617.2 or B.1.351 spike
glycoproteins. Each point is the mean of three replicates, violin plot illustrates median plus quartiles. Mean titres were
compared by one-way ANOVA. (G-J) Neutralising antibody titres were categorised based into the four viral variants
against which they were determined; Wuhan-Hu-1 (G), B.1.617.1 (H), B.1.617.2 (I) or B.1.351 (J). Samples were then
subdivided into one or two doses of BNT162b2 or ChAdOx1 respectively for each variant and compared (one-way
ANOVA, Tukey’s multiple comparison’s test). Vaccination with two doses of BNT162b2 induced significantly higher
titres of antibody against the Wuhan-Hu-1 virus than either one dose of BNT162b2, or two doses of ChAdOx1 (����
p<0.0001, �� p = 0.0011).
https://doi.org/10.1371/journal.ppat.1010022.g003
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infectivity (luciferase activity) was reduced by 50%. Neutralizing antibodies were induced by
vaccination with both the BNT162b2 (Fig 3C and 3D) and ChAdOx1 (Fig 3E and 3F) vaccines
and two doses of either vaccine boosted the titre of neutralizing antibodies. Antibody titres
were greatest against the Wuhan-Hu-1 spike glycoprotein and lower against the variants
B.1.617.1, B.1.617.2 or B.1.351. Samples from all individuals vaccinated with two doses of
BNT162b2 neutralised Wuhan-Hu-1 efficiently (mean titre = 11473, n = 50), however, mean
antibody titres against the variants B.1.671.1, B.1.617.2 and B.1.351 were reduced by 7.77-fold,
11.30-fold and 9.56-fold respectively (significant, p<0.0001) (S2 Table). The mean antibody
titre induced by vaccination with two doses of ChAdOx1 (mean titre = 1325.6, n = 18) was sig-
nificantly lower than that induced by two doses of BNT162b2 (mean titre = 11473) (Fig 3G
and S2 Table). After a single dose of ChAdOx1, 17 of 50 of vaccinated individuals (34%) had
antibody titres�50. In comparison, only 5 of 37 individuals (13.5%) vaccinated with a single
dose of BNT162b2 had antibody titres�50. These data are consistent with ChAdOx1 inducing
a weaker antibody response than BNT162b2 following primary immunisation. Comparison of
antibody responses measured by ELISA and by pseudotype-based neutralisation assay (S1 Fig)
illustrated the marked difference between the responses elicited by one or two doses of vaccine.
After the first dose of either BNT162b2 or ChAdOx1, antibody responses varied greatly, from
very low (negative in both assay formats) to high (positive in both formats). Two doses of
BNT162b2 elicited higher antibody titres than two doses of ChAdOx1. Stratification of the
data into three groups based on titre (<50; 50 to 500; and>500) (S2 Fig) illustrated the reduc-
tion in neutralisation of the variants; only the samples from individuals given two doses of
BNT162b2 retained measurable neutralising activity against the three variants, B.1.617.1,
B.1.617.2 and B.1.351. After two doses of ChAdOx1, all samples displayed neutralising activity
against Wuhan-hu-1, however only 55.6% neutralised B.1.617.1, 83.4% neutralised B.1.617.2,
and 61.1% neutralised B.1.351.
The mean titre of antibodies detected in individuals vaccinated with BNT162b2 against all
the VOCs analysed was higher than those present in sera from individuals vaccinated with
ChAdOx1 (Fig 3G–3J). Vaccination with two doses of BNT162b2 induced significantly higher
neutralising antibody titres against the Wuhan-Hu-1 virus than either one dose of BNT162b2,
or two doses of ChAdOx1. Although the mean neutralising antibody titres against the variants
were lower than those against the Wuhan-hu-1 vaccine strain, titres against Wuhan-hu-1 cor-
related broadly with the cross-neutralising titres against the variants B.1.617.1, B.1.617.2 and
B.1.351 (S3 Fig and S3 Table).
When the age distribution of the study cohorts was compared, it was notable that the partic-
ipants vaccinated with the ChAdOx1 vaccine were on average 15 years older than those vacci-
nated with BNT162b2 (43 versus 58 respectively; S2 Table and S4 Fig), consistent with the
shifting governmental policy on age-group targeting mid-study. Insufficient samples were
available from younger participants (ChAdOx1) or older participants (BNT162b2) to examine
the effects of age on antibody response.
Discussion
The Delta variant B.1.617.2 that originated in India has rapidly become the dominant lineage
in the UK. This variant is characterised by mutations in the genome that are associated with
immune escape in other SARS-CoV-2 lineages. In this study, we aimed to investigate the neu-
tralisation profile of sera from participants in the DOVE deployed vaccine cohort study against
B.1.617 sub-lineage variants. We compared neutralisation of B.1.617 variants with the original
Wuhan-Hu-1 virus that has been used as the prototype for all currently deployed vaccines and
the B.1.351 variant that originated in South Africa. The B.1.351 variant has been shown to be
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associated with reduced neutralisation and breakthrough infection in clinical trials [17]. We
aimed to quantify neutralisation profiles from sera obtained from recipients of the BNT162b2
and ChAdOx1 vaccines after one or two doses of vaccine, informing the UK strategy of maxi-
mising first dose rollout of vaccination in the population.
Our study showed that using the HIV (SARS-CoV-2) pseudotype-based system, neutralisa-
tion of the B.1.617.1, B.1.617.2 and B.1.351 variants was significantly lower in magnitude in
comparison with the Wuhan-Hu-1 variant in participants vaccinated either with BNT162b2 or
ChAdOx1, while two doses of BNT162b2 induced significantly higher neutralizing antibody
titres against the Wuhan-Hu-1 and B.1.351 variants than one dose. Previous studies looked at
the antibody resistance of B.1.351 and noted a reduction in sensitivity of 10.3-fold and
12.4-fold in sera from BNT162b2 (Pfizer)-vaccinated and mRNA-1273 (Moderna)-vaccinated
individuals respectively, using a vesicular stomatitis virus (VSV) pseudotype-based assay [8]
while live virus-based microneutralisation assays revealed a reduction of 8 to 14-fold in the
neutralisation of B.1.351 by convalescent plasma [18]. Despite using distinct technical
approaches to measuring neutralising antibody responses, the reductions in magnitude
observed in our study (9.56-fold for B.1.351) and prior studies [8,18] are broadly similar,
hence we can have confidence in concomitant estimates of the magnitude of neutralisation
escape by variants B.1.617.1 and B.1.617.2. A recent study using sera from individuals vacci-
nated with BNT162b2 employed a high-throughput, live virus microneutralisation assay and
observed a more modest reduction in neutralisation of 4.9-fold for B.1.351 and 5.8-fold for
B.1.617.2 [19], perhaps reflecting subtle differences in the parameters being measured by live
virus based assays using virus cultured in Vero E6 cells (viral entry, replication and spread)
and pseudotype based assays (viral entry and transfer vector gene expression only). More mod-
est escape from neutralisation by vaccine sera by B.1.617.1 (2.7-fold for BNT162b2) and
B.1.617.2 (2.5-fold for BNT162b2) was noted by Liu et al. [20]. This more modest effect may
reflect a combination of variables: the reference strain was SARS-CoV-2/human/AUS/VIC01/
2020 (S247R) and not Wuhan-hu-1, with both the Victoria and B.1.617.2 (A222V) viruses
grown in Vero cells. Further, the BNT162b2 vaccine sera came from a compressed schedule
study (4–14 days after 2 doses 3 weeks apart), while BNT162b2 vaccinated individuals in our
study were given 2 doses 9–10 weeks apart. Finally, BNT162b2 titres against Victoria and
B.1.617.2 were estimated using a focus reduction neutralisation test (FRNT) [20] as opposed to
a pseudotype-based neutralisation assay in this study.
It was notable that both our study and Wall et al [19] used sera from “real world” vaccinated
individuals rather than clinical trial participants and both showed a significant increase in neu-
tralisation after two vaccine doses. In contrast, recent data from 20 sera collected from clinical
trial participants vaccinated with BNT162b2 showed relatively similar levels of neutralising
antibodies against B.1.617.1, B.1.617.2, B.1.618 (all first identified in India) and B.1.525 (first
identified in Nigeria) using a live virus assay (plaque reduction assay) [21]. In that study, geo-
metric mean plaque reduction neutralization titres against the variant viruses appeared lower
than the titre against USA-WA1/2020, an early Wuhan-Hu-1-like virus, however all sera tested
neutralized the variant viruses at titres of at least 40 and displayed very uniform titres against
each variant (albeit titres for B.1.617.1 were somewhat lower). Those results contrast with the
spread of neutralising antibody levels across variants observed in our study and in Wall et al
[19]. These discrepancies may be due to the source and number of the sera analysed or to the
methodology used.
The mean titre of antibodies detected in individuals vaccinated with BNT162b2 against all
the VOCs analysed was higher than those present in sera from individuals vaccinated with
ChAdOx1. Vaccination with two doses of BNT162b2 induced significantly higher neutralising
antibody titres against the Wuhan-Hu-1 virus than either one dose of BNT162b2, or two doses
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of ChAdOx1. Further, the mean antibody titre induced by vaccination with two doses of ChA-
dOx1 was significantly lower than that induced by two doses of BNT162b2. Levels of neutralis-
ing antibody detected post-vaccination correlate strongly with the degree of protection from
infection afforded [22,23]. Hence the differences we observed in levels of neutralising antibody
elicited by BNT162b2 and ChAdOx1, and the reductions in cross-neutralisation against the
VOCs in comparison with the vaccine strain Wuhan-hu-1, suggest that the degree of immu-
nity afforded by vaccination will vary depending on the variants currently circulating in the
community and the vaccines employed. Continuous surveillance of neutralising responses
against VOCs will provide a valuable tool for predicting the likely efficacy of vaccines in cur-
tailing the spread of novel variants.
Due to vaccines being used in batches targeted at decreasing age groups in the UK, compar-
isons between neutralisation responses in recipients of the ChAdOx1 versus the BNT162b2,
vaccine responses may also be affected by age differences between these groups [19,24]. For
example, in this study, participants vaccinated with the ChAdOx1 were on average 15 years
older than those vaccinated with BNT162b2. Hence the effects of age will need further investi-
gation as samples from broader populations of age-matched individuals become available.
In summary, we found that the B.1.617.2 variant, currently dominant in the UK is associ-
ated with significantly reduced neutralisation from vaccine sera obtained from recipients of
the BNT162b2 or ChAdOx1 vaccines. Neutralisation titres were higher following two doses of
vaccine. These data are in keeping with recent vaccine effectiveness studies published by Public
Health England (PHE) and Public Health Scotland (PHS), in which test negative case control
designs were used to estimate the effectiveness of vaccination against symptomatic disease
[3,25]. In the PHE study, data on all symptomatic sequenced cases of COVID-19 in England
was used to estimate the proportion of cases with B.1.617.2 compared to the preceding B.1.1.7
variant by vaccination status. Effectiveness was found to be lower after one dose of vaccine
with B.1.617.2 (33.5%) compared to B.1.1.7 (51.1%), with similar results for both vaccines.
After two doses of BNT162b2 vaccine, effectiveness reduced from 93.4% with B.1.1.7 to 87.9%
with B.1.617.2. Following two doses of ChAdOx1, effectiveness reduced from 66.1% with
B.1.1.7 to 59.8% with B.1.617.2. In addition, sequenced cases detected after one or two doses of
vaccination had a higher odd of infection with B.1.617.2 compared to unvaccinated cases (OR
1.40; 95%CI: 1.13–1.75). The PHS data from the EAVE-2 study employed S gene dropout sta-
tus (a non-exclusive marker of the B.1.1.7 lineage but not the B.1.617.2 lineage) to estimate
vaccine effectiveness. The BNT162b2 vaccine was found to be 92% in the S gene-negative
group (inferred as B.1.1.7) versus 79% in the S gene-positive group (inferred as B.1.617.2). The
ChAdOx1 vaccine was reduced from 73% in S gene-negative cases versus 60% in S gene-posi-
tive ones. These data and ours suggest that pseudotype-based neutralisation assays are likely to
reveal correlates of immunity to SARS-CoV-2 virus variants and further investigation to corre-
late neutralisation titres with vaccine failure is warranted.
The UK strategy for prioritisation of one-dose vaccination of the population with a second
dose within 12 weeks is strongly associated with a significant reduction in deaths and hospitali-
sation associated with COVID-19 infection. However, the emergence of the B.1.617.2 variant
(or others with similar neutralisation profiles, such as B.1.351) may necessitate a modified
approach, to counter the increase in infections observed with the B.1.617.2 variant in the UK.
More positively, despite the lower humoral response observed, hospitalisation rates of vacci-
nated people remain low. This indicates that vaccine-elicited immune responses can moderate
disease severity even in the face of a reduction in the antibody response. High transmission
rates of the B.1.617.2 variant in single-dose vaccine recipients or those previously infected with
another variant may risk the evolution of vaccine-adapted variants. Further, reduction in titres
over time may be expected to be associated with vaccine failure in those who have received
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two doses of vaccine. Trials investigating whether a third dose of vaccine based on the original
Wuhan-Hu-1 virus or adapted virus variants will help to prevent symptomatic infection with
B.1.617.2 and future virus variants are underway (COV-BOOST https://www.covboost.org.uk/
home).
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